What Can Ribo-Seq, Immunopeptidomics, and Proteomics Tell Us About the Noncanonical Proteome?


Journal

Molecular & cellular proteomics : MCP
ISSN: 1535-9484
Titre abrégé: Mol Cell Proteomics
Pays: United States
ID NLM: 101125647

Informations de publication

Date de publication:
09 2023
Historique:
received: 14 05 2023
revised: 21 07 2023
accepted: 08 08 2023
medline: 25 9 2023
pubmed: 13 8 2023
entrez: 12 8 2023
Statut: ppublish

Résumé

Ribosome profiling (Ribo-Seq) has proven transformative for our understanding of the human genome and proteome by illuminating thousands of noncanonical sites of ribosome translation outside the currently annotated coding sequences (CDSs). A conservative estimate suggests that at least 7000 noncanonical ORFs are translated, which, at first glance, has the potential to expand the number of human protein CDSs by 30%, from ∼19,500 annotated CDSs to over 26,000 annotated CDSs. Yet, additional scrutiny of these ORFs has raised numerous questions about what fraction of them truly produce a protein product and what fraction of those can be understood as proteins according to conventional understanding of the term. Adding further complication is the fact that published estimates of noncanonical ORFs vary widely by around 30-fold, from several thousand to several hundred thousand. The summation of this research has left the genomics and proteomics communities both excited by the prospect of new coding regions in the human genome but searching for guidance on how to proceed. Here, we discuss the current state of noncanonical ORF research, databases, and interpretation, focusing on how to assess whether a given ORF can be said to be "protein coding."

Identifiants

pubmed: 37572790
pii: S1535-9476(23)00142-1
doi: 10.1016/j.mcpro.2023.100631
pmc: PMC10506109
pii:
doi:

Substances chimiques

Proteome 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

100631

Subventions

Organisme : NCI NIH HHS
ID : K08 CA263552
Pays : United States
Organisme : NIGMS NIH HHS
ID : R01 GM087221
Pays : United States
Organisme : NIA NIH HHS
ID : U19 AG023122
Pays : United States
Organisme : NCI NIH HHS
ID : P01 CA206978
Pays : United States
Organisme : NCI NIH HHS
ID : U24 CA270823
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA271402
Pays : United States
Organisme : NCI NIH HHS
ID : U24 CA271075
Pays : United States
Organisme : Wellcome Trust
ID : 108749/Z/15/Z
Pays : United Kingdom
Organisme : NHGRI NIH HHS
ID : U41 HG007234
Pays : United States

Commentaires et corrections

Type : UpdateOf

Informations de copyright

Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Conflict of interest The authors declare no competing interests.

Auteurs

John R Prensner (JR)

Division of Pediatric Hematology/Oncology, Department of Pediatrics, University of Michigan Medical School, Ann Arbor, Michigan, USA; Department of Biological Chemistry, University of Michigan Medical School, Ann Arbor, Michigan, USA. Electronic address: prensner@umich.edu.

Jennifer G Abelin (JG)

Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.

Leron W Kok (LW)

Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.

Karl R Clauser (KR)

Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.

Jonathan M Mudge (JM)

European Molecular Biology Laboratory, European Bioinformatics Institute, Wellcome Genome Campus, Cambridge, UK.

Jorge Ruiz-Orera (J)

Cardiovascular and Metabolic Sciences, Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany.

Michal Bassani-Sternberg (M)

Ludwig Institute for Cancer Research, Agora Center Bugnon 25A, University of Lausanne, Lausanne, Switzerland; Department of Oncology, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland; Agora Cancer Research Centre, Lausanne, Switzerland.

Robert L Moritz (RL)

Institute for Systems Biology (ISB), Seattle, Washington, USA.

Eric W Deutsch (EW)

Institute for Systems Biology (ISB), Seattle, Washington, USA.

Sebastiaan van Heesch (S)

Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH